US-based medical technology firm Medtronic received clearance by the Federal Trade Commission this week to merge with Ireland-based Covidien, a deal that will see Medtronic relocate its tax bracket abroad for lower rates.
According to reports, Medtronic has been cleared to buy Covidien for $42.9 billion. Medtronic, however, will have to divest its drug-coated balloon catheter operations to appease competition concerns, reports say.
The deal was first announced last June and will boost Medtronic’s standing in the global medical technology industry to compete more closely with industry leader Johnson & Johnson. The deal must also secure approval by regulators in China and the EU, reports say; Canada cleared the plans Wednesday.
Full content: The Independent
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Redfin Settles $9.2M Commission Inflation Lawsuits
May 7, 2024 by
CPI
DOJ Supports Colorado’s Efforts to Block Kroger-Albertsons Merger
May 7, 2024 by
CPI
Japan Considers Regulation of AI Developers
May 7, 2024 by
CPI
European Commission Extends Decision Deadline for Ita-Lufthansa Merger
May 7, 2024 by
CPI
UK, US and Australia Sanction Senior Leader of LockBit Cybercrime Gang
May 7, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Economics of Criminal Antitrust
Apr 19, 2024 by
CPI
Navigating Economic Expert Work in Criminal Antitrust Litigation
Apr 19, 2024 by
CPI
The Increased Importance of Economics in Cartel Cases
Apr 19, 2024 by
CPI
A Law and Economics Analysis of the Antitrust Treatment of Physician Collective Price Agreements
Apr 19, 2024 by
CPI
Information Exchange In Criminal Antitrust Cases: How Economic Testimony Can Tip The Scales
Apr 19, 2024 by
CPI